{
    "1674092193592516612": {
        "attachments": {
            "media_keys": [
                "3_1674092190992154624"
            ]
        },
        "author_id": "5383942",
        "created_at": "2023-06-28T16:27:36.000Z",
        "edit_history_tweet_ids": [
            "1674092193592516612"
        ],
        "entities": {
            "hashtags": [
                {
                    "end": 107,
                    "start": 104,
                    "tag": "TB"
                }
            ],
            "mentions": [
                {
                    "end": 15,
                    "id": "19837528",
                    "start": 1,
                    "username": "wellcometrust"
                },
                {
                    "end": 36,
                    "id": "17899109",
                    "start": 20,
                    "username": "gatesfoundation"
                }
            ],
            "urls": [
                {
                    "display_url": "pic.twitter.com/SaX2PsQaSq",
                    "end": 302,
                    "expanded_url": "https://twitter.com/GSK/status/1674092193592516612/photo/1",
                    "media_key": "3_1674092190992154624",
                    "start": 279,
                    "url": "https://t.co/SaX2PsQaSq"
                }
            ]
        },
        "id": "1674092193592516612",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 1,
            "impression_count": 6102,
            "like_count": 29,
            "quote_count": 0,
            "reply_count": 5,
            "retweet_count": 6
        },
        "text": ".@wellcometrust and @gatesfoundation announce funding to advance M72/AS01E, a candidate vaccine against #TB. We\u2019re proud to have led on its early development. If successful in Phase 3, it'll be the first new vaccine against active TB in over a century in lower income countries. https://t.co/SaX2PsQaSq"
    }
}